Table 1.
Characteristics and demographics of COVID-19 Patients.
| Total (N = 39) | IMV-alone (N = 21) | RVAD/ECMO (N = 18) | P value | |
| Age (y) | 53 (44-61) | 58 (42-67) | 51 (44-57) | 0.17 |
| Gender | 0.43 | |||
| Female | 20 (51.3%) | 12 (57.1%) | 8 (44.4%) | |
| Male | 19 (48.7%) | 9 (42.9%) | 10 (55.6%) | |
| PaO2/FiO2 ratio | 83 (68.4-96.7) (N = 31) |
93.3 (71-106) (N = 17) |
71.9 (62-85) (N = 14) |
0.039 |
| SpO2/FiO2 ratio | 88.5 (82-99) (N = 24) |
91.5 (83.5-101.4) (N = 20) |
68.5 (50-86) (N = 4) |
0.063 |
| Race | 0.49 | |||
| African American | 19 (48.7%) | 12 (57.1%) | 7 (38.9%) | |
| Non-Hispanic White | 12 (30.8%) | 6 (28.6%) | 6 (33.3%) | |
| Other race/ethnicity | 8 (20.5%) | 3 (14.3%) | 5 (27.8%) | |
| Comorbidity count | 0.67 | |||
| <4 | 33 (84.6%) | 17 (80.9%) | 16 (88.9%) | |
| 4-5 | 6 (15.4%) | 4 (19.1%) | 2 (11.1%) | |
| Comorbid condition | ||||
| Chronic lung disease | 13 (33.3%) | 6 (28.6%) | 7 (38.9%) | 0.50 |
| Hypertension | 22 (56.4%) | 13 (61.9%) | 9 (50.0%) | 0.46 |
| Coronary artery disease | 3 (7.7%) | 0 (0%) | 3 (16.7%) | 0.089 |
| Chronic kidney disease | 3 (7.7%) | 2 (9.5%) | 1 (5.6%) | 1.00 |
| Preoperative hemodialysis | 0 (0%) | 0 (0%) | 0 (0%) | |
| Diabetes mellitus | 15 (38.5%) | 9 (42.9%) | 6 (33.3%) | 0.54 |
| Obesity | 25 (64.1%) | 14 (66.7%) | 11 (61.1%) | 0.72 |
| Therapies given | ||||
| Hydroxychloroquine | 24 (75%) (N = 32) |
16 (76.2%) (N = 21) |
8 (72.7%) (N = 11) |
0.83 |
| Azithromycin | 24 (75%) (N = 32) |
18 (85.7%) (N = 21) |
6 (54.6%) (N = 11) |
0.053 |
| Doxycycline | 11 (34.4%) (N = 32) |
6 (28.6%) (N = 21) |
5 (45.5%) (N = 11) |
0.44 |
| Tocilizumab | 16 (41.0%) (N = 39) |
5 (23.8%) (N = 21) |
11 (61.1%) (N = 18) |
0.025 |
| Prednisone | 7 (21.9%) (N = 32) |
4 (19.1%) (N = 21) |
3 (27.3%) (N = 11) |
0.67 |
| Hydrocortisone | 5 (15.6%) (N = 32) |
4 (19.1%) (N = 21) |
1 (9.1%) (N = 11) |
0.64 |
| Dexamethasone | 7 (21.9%) (N = 32) |
6 (28.6%) (N = 21) |
1 (9.1%) (N = 11) |
0.37 |
| Convalescent plasma | 14 (35.9%) (N = 39) |
2 (9.5%) (N = 21) |
12 (66.7%) (N = 18) |
0.001 |
| Remdesivir | 2 (6.3%) (N = 32) |
2 (9.5%) (N = 21) |
0 (0%) (N = 11) |
0.53 |
| Proning | 37 (97.4%) (N = 38) |
19 (95%) (N = 20) |
18 (100%) (N = 18) |
1.00 |
IMV = invasive mechanical ventilation; RVAD/ECMO = right ventricular assist device/extracorporeal membrane oxygenation.
Bold text indicates p-value is significant (i.e. p<0.05).